Skip NavigationSkip to Content
Return Return to Search Results

Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model

  1. Author:
    Igarashi, Kentaro
    Kawaguchi, Kei
    Kiyuna, Tasuku
    Miyake, Kentaro
    Higuchi, Takashi
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Miwa, Shinji
    Singh,Shree Ram
    Tsuchiya, Hiroyuki
    Hoffman, Robert M

  2. Author Address

    AntiCancer, Inc., San Diego, CA, U.S.A., Department of Surgery, University of California, San Diego, CA, U.S.A., Department of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan., Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com tsuchi@med.kanazawa-u.ac.jp singhshr@mail.nih.gov., Department of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan all@anticancer.com tsuchi@med.kanazawa-u.ac.jp singhshr@mail.nih.gov., AntiCancer, Inc., San Diego, CA, U.S.A. all@anticancer.com tsuchi@med.kanazawa-u.ac.jp singhshr@mail.nih.gov.,
    1. Year: 2020
    2. Date: Jul-Aug
  2. Journal: Cancer genomics & proteomics
    1. 17
    2. 4
    3. Pages: 351-358
  4. Type of Article: Article
  5. ISSN: 1109-6535
  1. Abstract:

    Background/aim: Dedifferentiated liposarcoma (DDLPS) is recalcitrant type of sarcoma. DDLPS has a low survival rate with high recurrence and metastasis. In the present study, we evaluated the efficacy of several drugs against doxorubicin-resistant DDLPS in a patient-derived orthotopic xenograft (PDOX) model for precision oncology. To establish the PDOX model, a tumor from a patient who had recurrent high-grade DDLPS from the retroperitoneum was previously grown orthotopically in the retroperitoneum of nude mice. Materials and methods: We randomized DDLPS PDOX models into 8 treatment groups when tumor volume became approximately 100 mm3: control, no treatment; G2, doxorubicin (DOX); G3, pazopanib (PAZ); G4, gemcitabine (GEM) combined with docetaxel (DOC); G5, trabectedin (YON); G6, temozolomide (TEM); G7, palbociclib (PAL); G8, eribulin (ERB). Tumor length and width were measured both at the beginning and at the end of treatment. Results: At the end of treatment (day 14), all treatments significantly inhibited DDLPS PDOX tumor growth compared to the untreated control, except DOX. ERB was significantly more effective and regressed tumor volume compared to other treatments on day 14 after initiation of treatment. No significant differences were found in the relative body weight on day 14 compared to day 0 in any group. Conclusion: The clinical potential of ERB against DDLPS is herein presented in a PDOX model. Keywords: PDOX; Patient-derived orthotopic xenograft; dedifferentiated liposarcoma; doxorubicin resistance; eribulin; regression. Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.21873/cgp.20194
  3. PMID: 32576580
  4. View record in Web of Science®
  5. WOS: 000543371300003
  6. PII : 17/4/351

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel